What is Lantern Pharma Inc's earnings per share (EPS)?

Lantern Pharma Inc (LTRN) reported diluted earnings per share of $-1.57 for fiscal year 2025. This represents a 18.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lantern Pharma Inc Financials

LTRN

Source SEC Filings (10-K/10-Q) Updated Mar 30, 2026 Currency USD FYE March

This page shows Lantern Pharma Inc (LTRN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Lantern Pharma Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.92x

For every $1 of reported earnings, Lantern Pharma Inc generates $0.92 in operating cash flow (-$15.7M OCF vs -$17.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$18.0M

YoY+19.1%

Lantern Pharma Inc's EBITDA was -$18.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.1% from the prior year.

Net Income

-$17.1M

YoY+17.6%

Lantern Pharma Inc reported -$17.1M in net income in fiscal year 2025. This represents an increase of 17.6% from the prior year.

EPS (Diluted)

$-1.57

YoY+18.7%

Lantern Pharma Inc earned $-1.57 per diluted share (EPS) in fiscal year 2025. This represents an increase of 18.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$15.7M

YoY+12.0%

Lantern Pharma Inc generated -$15.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 12.0% from the prior year.

Cash & Debt

$4.4M

YoY-41.1%

5Y CAGR-25.5%

Lantern Pharma Inc held $4.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

11M

YoY+4.4%

5Y CAGR+12.6%

Lantern Pharma Inc had 11M shares outstanding in fiscal year 2025. This represents an increase of 4.4% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-262.0%

YoY-163.9pp

5Y CAGR-232.0pp

Lantern Pharma Inc's ROE was -262.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 163.9 percentage points from the prior year.

Capital Allocation

R&D Spending

$11.5M

YoY-28.6%

5Y CAGR+38.7%

Lantern Pharma Inc invested $11.5M in research and development in fiscal year 2025. This represents a decrease of 28.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$2K

YoY-86.4%

Lantern Pharma Inc invested $2K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 86.4% from the prior year.

LTRN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$11.5M-28.6%	$16.1M+35.6%	$11.9M+38.3%	$8.6M+13.6%	$7.6M+237.5%	$2.2M
SG&A Expenses	$6.5M+6.1%	$6.1M+1.8%	$6.0M+2.6%	$5.8M+16.1%	$5.0M+37.0%	$3.7M
Operating Income	-$18.0M+19.1%	-$22.2M-24.3%	-$17.9M-23.9%	-$14.4M-14.6%	-$12.6M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$17.1M+17.6%	-$20.8M-30.2%	-$16.0M-11.9%	-$14.3M-15.3%	-$12.4M-109.3%	-$5.9M
EPS (Diluted)	$-1.57+18.7%	$-1.93-31.3%	$-1.47-12.2%	$-1.31	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$2.4M-20.6%	$3.1M-6.0%	$3.3M	N/A	$3.7M-4.4%	$3.9M-8.5%	$4.3M	N/A
SG&A Expenses	$1.9M+20.8%	$1.6M+4.9%	$1.5M	N/A	$1.5M-3.7%	$1.5M+2.6%	$1.5M	N/A
Operating Income	-$4.3M+6.5%	-$4.7M+2.6%	-$4.8M	N/A	-$5.2M+4.2%	-$5.4M+5.6%	-$5.7M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$4.2M+3.5%	-$4.3M+4.5%	-$4.5M	N/A	-$4.5M+9.2%	-$5.0M+8.8%	-$5.4M	N/A
EPS (Diluted)	$-0.39+2.5%	$-0.40+4.8%	$-0.42	N/A	$-0.42+8.7%	$-0.46+9.8%	$-0.51	N/A

LTRN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$11.0M-56.8%	$25.6M-41.4%	$43.6M-25.8%	$58.8M-20.4%	$74.0M+263.2%	$20.4M
Current Assets	$10.8M-57.2%	$25.2M-41.7%	$43.3M-26.2%	$58.7M-19.2%	$72.7M+259.3%	$20.2M
Cash & Equivalents	$4.4M-41.1%	$7.5M-65.8%	$21.9M-41.0%	$37.2M-27.8%	$51.5M+167.9%	$19.2M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.5M+2.7%	$4.4M+60.0%	$2.7M-2.1%	$2.8M+17.6%	$2.4M+260.0%	$661K
Current Liabilities	$4.5M+3.9%	$4.3M+61.7%	$2.7M-4.3%	$2.8M+20.3%	$2.3M+321.1%	$552K
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$6.5M-69.2%	$21.2M-48.2%	$40.9M-27.0%	$56.0M-21.7%	$71.6M+263.3%	$19.7M
Retained Earnings	-$93.1M-22.5%	-$76.0M-37.6%	-$55.2M-40.6%	-$39.3M-57.0%	-$25.0M-97.7%	-$12.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$13.6M-21.8%	$17.4M-17.4%	$21.1M-17.5%	$25.6M-15.6%	$30.3M-14.9%	$35.6M-10.4%	$39.7M-9.0%	$43.6M
Current Assets	$13.5M-21.7%	$17.2M-17.4%	$20.8M-17.5%	$25.2M-15.6%	$29.9M-15.2%	$35.3M-10.6%	$39.5M-8.9%	$43.3M
Cash & Equivalents	$8.4M+38.4%	$6.1M-5.0%	$6.4M-15.1%	$7.5M-7.3%	$8.1M-37.6%	$13.0M-29.3%	$18.4M-16.3%	$21.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$4.0M-17.5%	$4.9M+13.4%	$4.3M-1.5%	$4.4M+18.6%	$3.7M-20.6%	$4.7M+17.3%	$4.0M+44.9%	$2.7M
Current Liabilities	$4.0M-17.3%	$4.9M+13.9%	$4.3M-1.0%	$4.3M+20.3%	$3.6M-21.7%	$4.6M+16.4%	$4.0M+47.6%	$2.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.6M-23.4%	$12.5M-25.4%	$16.8M-20.8%	$21.2M-20.3%	$26.6M-14.0%	$30.9M-13.5%	$35.8M-12.6%	$40.9M
Retained Earnings	-$89.1M-4.9%	-$84.9M-5.4%	-$80.6M-6.0%	-$76.0M-8.4%	-$70.2M-6.9%	-$65.6M-8.2%	-$60.7M-9.8%	-$55.2M

LTRN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$15.7M+12.0%	-$17.8M-24.2%	-$14.3M-12.4%	-$12.8M-20.5%	-$10.6M-87.4%	-$5.7M
Capital Expenditures	$2K-86.4%	$13K-32.8%	$19K-32.7%	$28K+79.7%	$15K	N/A
Free Cash Flow	-$15.7M+12.0%	-$17.8M-24.1%	-$14.4M-12.3%	-$12.8M-20.6%	-$10.6M	N/A
Investing Cash Flow	$11.1M+228.2%	$3.4M+462.2%	-$930K-618.9%	$179K+100.9%	-$19.5M-120929.8%	-$16K
Financing Cash Flow	$1.5M+2145.9%	$67K+113.3%	-$500K+77.1%	-$2.2M-103.4%	$63.4M+168.0%	$23.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	$500K-79.9%	$2.5M+164.2%	$940K	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$4.6M-16.1%	-$3.9M+10.0%	-$4.4M-10.2%	-$4.0M+28.8%	-$5.6M-7.5%	-$5.2M-69.2%	-$3.1M+9.4%	-$3.4M
Capital Expenditures	$555	$0-100.0%	$1K-62.4%	$3K+1.8%	$3K-29.0%	$4K+92.5%	$2K-56.4%	$5K
Free Cash Flow	-$4.6M-16.1%	-$3.9M+10.0%	-$4.4M-10.1%	-$4.0M+28.8%	-$5.6M-7.5%	-$5.2M-69.2%	-$3.1M+9.4%	-$3.4M
Investing Cash Flow	$5.9M+65.0%	$3.6M+10.9%	$3.2M-6.0%	$3.4M+406.7%	$680K+436.7%	-$202K+63.7%	-$556K-317.1%	$256K
Financing Cash Flow	N/A	N/A	N/A	$0-100.0%	$12K	$0-100.0%	$55K	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

LTRN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-262.0%-163.9pp	-98.1%-59.1pp	-39.0%-13.6pp	-25.4%-8.2pp	-17.3%+12.7pp	-30.0%
Return on Assets	-155.1%-73.9pp	-81.3%-44.7pp	-36.6%-12.3pp	-24.2%-7.5pp	-16.7%+12.3pp	-29.0%
Current Ratio	2.40-3.4	5.83-10.4	16.18-4.8	20.99-10.3	31.26-5.4	36.64
Debt-to-Equity	0.69+0.5	0.21+0.1	0.07+0.0	0.05+0.0	0.030.0	0.03
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-43.6%-9.0pp	-34.6%-7.6pp	-27.0%	N/A	-16.9%-0.9pp	-16.0%-0.8pp	-15.2%	N/A
Return on Assets	-30.7%-5.8pp	-24.9%-3.3pp	-21.5%	N/A	-14.9%-0.9pp	-13.9%-0.3pp	-13.7%	N/A
Current Ratio	3.33-0.2	3.52-1.3	4.86-1.0	5.83-2.5	8.31+0.6	7.67-2.3	9.98-6.2	16.18
Debt-to-Equity	0.42+0.0	0.39+0.1	0.26+0.1	0.21+0.1	0.14-0.0	0.15+0.0	0.11+0.0	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Plus Therapeutics Inc PSTV

$27.9M

Renovaro RENB

$32.9M

Grace Therapeutics, Inc GRCE

$71.6M

Jasper Therapeutics Inc JSPR

$24.5M

LAVA Therapeutics N.V. LVTX

$45.8M

Frequently Asked Questions

Is Lantern Pharma Inc profitable?

No, Lantern Pharma Inc (LTRN) reported a net income of -$17.1M in fiscal year 2025.

What is Lantern Pharma Inc's EBITDA?

Lantern Pharma Inc (LTRN) had EBITDA of -$18.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Lantern Pharma Inc's return on equity (ROE)?

Lantern Pharma Inc (LTRN) has a return on equity of -262.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Lantern Pharma Inc's free cash flow?

Lantern Pharma Inc (LTRN) generated -$15.7M in free cash flow during fiscal year 2025. This represents a 12.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Lantern Pharma Inc's operating cash flow?

Lantern Pharma Inc (LTRN) generated -$15.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Lantern Pharma Inc's total assets?

Lantern Pharma Inc (LTRN) had $11.0M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Lantern Pharma Inc's capital expenditures?

Lantern Pharma Inc (LTRN) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Lantern Pharma Inc spend on research and development?

Lantern Pharma Inc (LTRN) invested $11.5M in research and development during fiscal year 2025.

How many shares does Lantern Pharma Inc have outstanding?

Lantern Pharma Inc (LTRN) had 11M shares outstanding as of fiscal year 2025.

What is Lantern Pharma Inc's current ratio?

Lantern Pharma Inc (LTRN) had a current ratio of 2.40 as of fiscal year 2025, which is generally considered healthy.

What is Lantern Pharma Inc's debt-to-equity ratio?

Lantern Pharma Inc (LTRN) had a debt-to-equity ratio of 0.69 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Lantern Pharma Inc's return on assets (ROA)?

Lantern Pharma Inc (LTRN) had a return on assets of -155.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Lantern Pharma Inc's cash runway?

Based on fiscal year 2025 data, Lantern Pharma Inc (LTRN) had $4.4M in cash against an annual operating cash burn of $15.7M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Lantern Pharma Inc's Piotroski F-Score?

Lantern Pharma Inc (LTRN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lantern Pharma Inc's earnings high quality?

Lantern Pharma Inc (LTRN) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.